Shorts Action: A Reversal for Acorda Therapeutics Incorporated (NASDAQ:ACOR) Is Near. The Stock Has Decrease in Shorts

November 23, 2016 - By Ellis Scott   ·   0 Comments

Shorts Action: A Reversal for Acorda Therapeutics Incorporated (NASDAQ:ACOR) Is Near. The Stock Has Decrease in Shorts

The stock of Acorda Therapeutics Incorporated (NASDAQ:ACOR) registered a decrease of 2.17% in short interest. ACOR’s total short interest was 4.69M shares in November as published by FINRA. Its down 2.17% from 4.80M shares, reported previously. With 512,500 shares average volume, it will take short sellers 9 days to cover their ACOR’s short positions. The short interest to Acorda Therapeutics Incorporated’s float is 12.21%. About 353,961 shares traded hands. Acorda Therapeutics Inc (NASDAQ:ACOR) has declined 30.01% since April 21, 2016 and is downtrending. It has underperformed by 35.34% the S&P500.

Acorda Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $999.14 million. The Firm is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. It currently has negative earnings. The Company’s commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza.

Insitutional Activity: The institutional sentiment decreased to 0.89 in 2016 Q2. Its down 0.24, from 1.13 in 2016Q1. The ratio worsened, as 32 funds sold all Acorda Therapeutics Inc shares owned while 45 reduced positions. 14 funds bought stakes while 73 increased positions. They now own 43.11 million shares or 7.66% less from 46.68 million shares in 2016Q1.
Renaissance Ltd Liability Co owns 232,900 shares or 0.01% of their US portfolio. Meeder Asset accumulated 2,259 shares or 0.01% of the stock. Ladenburg Thalmann Financial Serv holds 38 shares or 0% of its portfolio. Blackrock Lc has invested 0.01% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR). Metropolitan Life Insurance Communications New York last reported 0.01% of its portfolio in the stock. First Trust Advisors Ltd Partnership holds 12,579 shares or 0% of its portfolio. Teachers Retirement System Of The State Of Kentucky holds 0.01% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR) for 23,970 shares. Convergence Prtn Limited Co, a Wisconsin-based fund reported 20,130 shares. Blackrock holds 0% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR) for 13,065 shares. Deere Communications holds 22,455 shares or 0.03% of its portfolio. Intll Grp owns 32,517 shares or 0% of their US portfolio. Blackrock Grp Ltd holds 0% or 87,438 shares in its portfolio. Spark Investment Lc reported 292,400 shares or 0.7% of all its holdings. The Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Acorda Therapeutics Inc (NASDAQ:ACOR). Pnc Fincl Grp last reported 7,712 shares in the company.

Insider Transactions: Since June 8, 2016, the stock had 0 insider buys, and 5 insider sales for $168,893 net activity. $77,927 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) shares were sold by Wasman Jane. 1,086 shares with value of $30,224 were sold by RAUSCHER STEVEN M on Wednesday, June 8. $5,205 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) was sold by LAWRENCE DAVID. $41,877 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) was sold by Batycky Richard P..

Acorda Therapeutics Inc (NASDAQ:ACOR) Ratings Coverage

Out of 2 analysts covering Acorda Therapeutics (NASDAQ:ACOR), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Acorda Therapeutics has been the topic of 8 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The rating was initiated by Aegis Capital on Tuesday, September 1 with “Buy”. The stock of Acorda Therapeutics Inc (NASDAQ:ACOR) has “Neutral” rating given on Tuesday, August 25 by JP Morgan. Aegis Capital maintained the stock with “Buy” rating in Wednesday, January 6 report. The firm has “Market Perform” rating by Raymond James given on Tuesday, September 1. As per Tuesday, August 25, the company rating was maintained by Cowen & Co. As per Wednesday, March 30, the company rating was initiated by Goldman Sachs. The rating was maintained by Stifel Nicolaus on Tuesday, August 25 with “Buy”. The firm has “Buy” rating given on Tuesday, August 25 by TheStreet.

ACOR Company Profile

Acorda Therapeutics, Inc., incorporated on March 17, 1995, is a biopharmaceutical company. The Firm is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. The Company’s commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. The Company’s research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. The Company’s Ampyra (dalfampridine) Extended Release Tablets, 10 milligrams, is used as a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets, which are short-acting drugs for the management of spasticity, and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company’s pipeline of neurological therapies addresses a range of disorders, including MS, Parkinson’s disease, chronic post-stroke walking deficits (PSWD), epilepsy and migraine.

More news for Acorda Therapeutics Inc (NASDAQ:ACOR) were recently published by: Marketwatch.com, which released: “Acorda Therapeutics plummets as much as 13% on failed trial, discontinued drug …” on November 21, 2016. Fortune.com‘s article titled: “Acorda Therapeutics” and published on October 12, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ellis Scott


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>